RESUMEN
A simple, cost-effective and sensitive liquid chromatography-based bio-analytical method has been developed and validated for therapeutic drug monitoring of fluconazole (FLUC) in human serum. Integration of online mixed-mode solid-phase extraction (SPE) into the analytical system was the key for direct injection of untreated serum samples. A short protein-coated (PC) µBondapak CN silica column (PC-µB-CN-column) as a SPE tool and phosphate buffer saline (PBS) (pH 7.4) as an eluent were applied in the extraction step. PC-µB-CN-column operates in two different chromatographic modes. Using PBS, proteins were extracted from serum samples by size-exclusion liquid chromatography, while FLUC trapping was reversed-phase liquid chromatography dependent. FLUC was then eluted from the PC-µB-CN-column onto the quantification position using a mixture of acetonitrile-distilled deionized water (20:80, v/v) as an eluent and ODS analytical column. FLUC was separated at ambient temperature (22 ± 1 °C) and detected at 260 nm. The method was linear over the range of 200-10000 ng/mL. FLUC recovery in untreated serum samples ranged from 97.8 to 98.8% and showed good accuracy and precision. The reliability of the developed method was evaluated by studying the pharmacokinetic profile of FLUC in humans after an oral administration of a single 150 mg tablet.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Monitoreo de Drogas/métodos , Fluconazol/sangre , Fluconazol/aislamiento & purificación , Extracción en Fase Sólida/métodos , Cromatografía de Fase Inversa/métodos , Fluconazol/química , Fluconazol/farmacocinética , Humanos , Límite de Detección , Modelos Lineales , Masculino , Reproducibilidad de los ResultadosRESUMEN
OBJECTIVES: Critically ill patients in intensive care unit (ICU) are susceptible to infectious diseases, thus empirical therapy is recommended. However, the therapeutic effect in ICU patients is difficult to predict due to fluctuation in pharmacokinetics because of various factors. This problem can be solved by developing personalized medicine through therapeutic drug monitoring. However, when different measurement systems are used for various drugs, measurements are complicated and time consuming in clinical practice. In this study, we aimed to develop an assay using ultra-high performance liquid chromatography coupled with tandem mass spectrometry for simultaneous quantification of 12 antimicrobial agents commonly used in ICU: doripenem, meropenem, linezolid, tedizolid, daptomycin, ciprofloxacin, levofloxacin, pazufloxacin, fluconazole, voriconazole, voriconazole N-oxide which is a major metabolite of voriconazole, and posaconazole. DESIGN & METHODS: Plasma protein was precipitated by adding acetonitrile and 50% MeOH containing standard and labeled IS. The analytes were separated with an ACQUITY UHPLC CSH C18 column, under a gradient mobile phase consisting of water and acetonitrile containing 0.1% formic acid and 2 mM ammonium formate. RESULTS: The method fulfilled the criteria of US Food and Drug Administration for assay validation. The recovery rate was more than 84.8%. Matrix effect ranged from 79.1% to 119.3%. All the calibration curves showed good linearity (back calculation of calibrators: relative error ≤ 15%) over wide concentration ranges, which allowed determination of Cmax and Ctrough. Clinical applicability of the novel method was confirmed. CONCLUSIONS: We have developed an assay for simultaneous quantification of 12 antimicrobial agents using a small sample volume of 50 µL with a short assay time of 7 min. Our novel method may contribute to simultaneous calculation of pharmacokinetic and pharmacodynamic parameters.
Asunto(s)
Antiinfecciosos/sangre , Antiinfecciosos/farmacocinética , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Anciano , Anciano de 80 o más Años , Antiinfecciosos/farmacología , Azoles/sangre , Carbapenémicos/sangre , Ciprofloxacina/sangre , Daptomicina/sangre , Doripenem/sangre , Monitoreo de Drogas/métodos , Femenino , Fluconazol/sangre , Fluoroquinolonas/sangre , Humanos , Unidades de Cuidados Intensivos , Levofloxacino/sangre , Linezolid/sangre , Masculino , Meropenem/sangre , Staphylococcus aureus Resistente a Meticilina/metabolismo , Persona de Mediana Edad , Oxazinas/sangre , Oxazolidinonas/sangre , Quinolonas/sangre , Tetrazoles/sangre , Voriconazol/sangreRESUMEN
BACKGROUND: Gilteritinib, a novel, potent FLT3/AXL inhibitor, was recently approved in Japan and USA for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. PURPOSE AND METHODS: In this study, we aimed to develop and validate a sensitive and simple ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the quantification of gilteritinib in plasma and to investigate whether CYP3A4 inhibitors (fluconazole and itraconazole) could influence the pharmacokinetics of gilteritinib from a drug-drug interaction study in rats. Sample preparation was done by a simple protein crash with acetonitrile containing the internal standard (IS) pirfenidone, followed by UPLC-MS/MS quantification. RESULTS: The assay was successfully validated in a 1-500 ng/mL calibration range for gilteritinib, where the lower limit of quantification (LLOQ) was set at 1 ng/mL. The intra-day and inter-day precisions for gilteritinib were less than 10.6%, and the accuracies were in the range of -14.5% to 11.1%. Recovery and matrix effect of the analyte and IS were acceptable, and the analyte was stable during the assay and storage in plasma samples. The validated UPLC-MS/MS method was successfully applied to a drug-drug interaction study between gilteritinib and CYP3A4 inhibitors (fluconazole and itraconazole) in rats. Itraconazole significantly increased the exposure of gilteritinib, and affected the pharmacokinetics of gilteritinib in rats, not fluconazole. CONCLUSION: A further clinical study should be conducted to investigate the effect of itraconazole on the metabolism of gilteritinib in subjects.
Asunto(s)
Compuestos de Anilina/sangre , Fluconazol/sangre , Itraconazol/sangre , Pirazinas/sangre , Administración Oral , Compuestos de Anilina/administración & dosificación , Compuestos de Anilina/farmacocinética , Animales , Cromatografía Líquida de Alta Presión , Interacciones Farmacológicas , Fluconazol/administración & dosificación , Fluconazol/farmacocinética , Itraconazol/administración & dosificación , Itraconazol/farmacocinética , Masculino , Pirazinas/administración & dosificación , Pirazinas/farmacocinética , Ratas , Ratas Sprague-Dawley , Espectrometría de Masas en TándemRESUMEN
Fluconazole and voriconazole are the two broad-spectrum triazole antifungals. The present work described the fabrication method for the synthesis of the amino-modified magnetic metal-organic framework. This material was applied as a pre-sample treatment sorbent for the selective extraction of fluconazole and voriconazole in rat plasma samples. The material was fabricated by the chemical bonding approach method and was characterized by different parameters. The factors which affect the extraction efficiency of the sorbent material were also optimized in this study. Due to the optimization of solid-phase extraction conditions, the nonspecific interaction was reduced and the extraction recoveries of target drugs were increased in plasma samples. The extraction method was combined with the HPLC-UV method for the analysis. Excellent linearity (0.1-25 µg/mL), detections (0.02, 0.03 µg/mL) and quantification limits (0.04, 0.05 µg/mL) were resulted for fluconazole and voriconazole respectively. The maximum recoveries from spiked plasma samples of fluconazole and voriconazole were 86.8% and 78.6% and relative standard deviation were 0.9-2.8% and 2.2-3.6% respectively. Moreover, this sorbent material was used multiple times which was an improvement over single-use commercial sorbent materials. This validated method has practical potential for the simultaneous determination of these drugs in therapeutic drug monitoring studies as well as for routine pharmacokinetic evaluations.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Fluconazol , Extracción en Fase Sólida/métodos , Voriconazol , Animales , Fluconazol/sangre , Fluconazol/aislamiento & purificación , Límite de Detección , Modelos Lineales , Nanopartículas de Magnetita/química , Estructuras Metalorgánicas/química , Ratas , Reproducibilidad de los Resultados , Voriconazol/sangre , Voriconazol/aislamiento & purificaciónRESUMEN
AIM: The aim of this study was to build and verify a preliminary physiologically based pharmacokinetic (PBPK) model of Chinese pregnant women. The model was used to predict maternal pharmacokinetics (PK) of 6 predominantly renally cleared drugs. METHOD: Based on SimCYP Caucasian pregnancy population dataset, the preliminary Chinese pregnant population was built by updating several key parameters and equations according to physiological parameters of Chinese (or Japanese) pregnant women. Drug-specific parameters of 6 renally cleared drugs were validated through PBPK modeling of Caucasian non-pregnant, Caucasian pregnant and Chinese non-pregnant population. The preliminary PBPK model of Chinese pregnant population was then developed by integrating the preliminary Chinese pregnant population and the drug-specific parameters. This model was verified by comparing the predicted maternal PK of these 6 drugs with the observed in vivo data from the literature. RESULTS: The preliminary Chinese pregnant population PBPK model successfully predicted the PK of 6 target drugs for different pregnancy stages. The predicted plasma concentrations time profiles fitted the observed data well, and most predicted PK parameters were within 2-fold of observed data. CONCLUSIONS: The preliminary Chinese pregnant population PBPK model provided a useful tool to predict the maternal PK of 6 predominantly renally cleared drugs in Chinese pregnant women.
Asunto(s)
Pueblo Asiatico , Riñón/metabolismo , Modelos Biológicos , Embarazo/metabolismo , Adulto , Aztreonam/sangre , Aztreonam/farmacocinética , Transporte Biológico , Ceftazidima/sangre , Ceftazidima/farmacocinética , Ceftriaxona/sangre , Ceftriaxona/farmacocinética , Cefuroxima/sangre , Cefuroxima/farmacocinética , Femenino , Fluconazol/sangre , Fluconazol/farmacocinética , Humanos , Imipenem/sangre , Imipenem/farmacocinética , Masculino , Persona de Mediana Edad , Población Blanca , Adulto JovenRESUMEN
Background Invasive fungal disease is a life-threatening condition that can be challenging to treat due to pathogen resistance, drug toxicity, and therapeutic failure secondary to suboptimal drug concentrations. Frequent therapeutic drug monitoring (TDM) is required for some anti-fungal agents to overcome these issues. Unfortunately, TDM at the institutional level is difficult, and samples are often sent to a commercial reference laboratory for analysis. To address this gap, the first paper spray-mass spectrometry assay for the simultaneous quantitation of five triazoles was developed. Methods Calibration curves for fluconazole, posaconazole, itraconazole, hydroxyitraconazole, and voriconazole were created utilizing plasma-based calibrants and four stable isotopic internal standards. No sample preparation was needed. Plasma samples were spotted on a paper substrate in pre-manufactured plastic cartridges, and the dried plasma spots were analyzed directly utilizing paper spray-mass spectrometry (paper spray MS/MS). All experiments were performed on a Thermo Scientific TSQ Vantage triple quadrupole mass spectrometer. Results The calibration curves for the five anti-fungal agents showed good linearity (R2 = 0.98-1.00). The measured assay ranges (lower limit of quantification [LLOQ]-upper limit of quantitation [ULOQ]) for fluconazole, posaconazole, itraconazole, hydroxyitraconazole, and voriconazole were 0.5-50 µg/mL, 0.1-10 µg/mL, 0.1-10 µg/mL, 0.1-10 µg/mL, and 0.1-10 µg/mL, respectively. The inter- and intra-day accuracy and precision were less than 25% over the respective ranges. Conclusions We developed the first rapid paper spray-MS/MS assay for simultaneous quantitation of five triazole anti-fungal agents in plasma. The method may be a powerful tool for near-point-of-care TDM aimed at improving patient care by reducing the turnaround time and for use in clinical research.
Asunto(s)
Antifúngicos/sangre , Pruebas con Sangre Seca/métodos , Monitoreo de Drogas/métodos , Papel , Fluconazol/sangre , Humanos , Marcaje Isotópico , Laboratorios/normas , Límite de Detección , Estándares de Referencia , Reproducibilidad de los Resultados , Espectrometría de Masas en Tándem , Triazoles/sangre , Voriconazol/sangreRESUMEN
BACKGROUND: Fluconazole represents a common antifungal option for the treatment of Candida infections in liver transplant recipients. Although adequate antifungal exposure is known to correlate with favorable outcomes in patients with invasive candidiasis, therapeutic drug monitoring (TDM) of fluconazole is currently not recommended. METHODS: We conducted a retrospective study including adult liver transplant recipients receiving fluconazole for invasive candidiasis and undergoing TDM. We assessed the correlation between clinical variables, fluconazole trough plasma levels (Cmin ), and outcome. RESULTS: Twenty-seven patients (74% males; median age 57 years) were included. Abdominal candidiasis was the most frequent infection (56%). Median duration of fluconazole therapy was 17 days (IQR 9-21). Fluconazole median Cmin was 11.0 mg/L (range 2.4-30.6 mg/L). Five (19%) patients required TDM-guided fluconazole dose increase. All-cause in hospital mortality was 33%. Fluconazole Cmin >11 mg/L significantly correlated with clinical success (OR 8.78, 95% CI 1.13-67.8, P = 0.04). CONCLUSIONS: Our study identified decreased fluconazole Cmin as a factor associated with negative outcomes in liver transplant recipients with Candida infection. TDM of fluconazole may be advisable in this patient population.
Asunto(s)
Antifúngicos/administración & dosificación , Candidiasis/tratamiento farmacológico , Monitoreo de Drogas , Fluconazol/administración & dosificación , Trasplante de Hígado/efectos adversos , Receptores de Trasplantes , Antifúngicos/sangre , Candidiasis Invasiva/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Femenino , Fluconazol/sangre , Mortalidad Hospitalaria , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Centros de Atención TerciariaRESUMEN
BACKGROUND: Candida spp is an etiologic agent of fungal infections in hospitals and resistance to treatment with antifungals has been extensively reported. Thus, it is very important to develop formulations that increase effectiveness with low toxicity. In this sense, nanocarriers have been investigated, once they modify drug biodistribution profile. Thus, this study aimed to evaluate the biodistribution of free and encapsulated 99mTc-fluconazole into nanocapsules (NCs) in an experimental immunosuppressed murine model of Candida albicans infection. METHODS: Fluconazole was radiolabeled with technetium-99 metastable (99mTc) and encapsulated into conventional (99mTc-Fluconazole-PLA-POLOX) and surface-modified (99mTc-Fluconazole-PLA-PEG) NCs by the interfacial deposition of the preformed biodegradable polymer [poly (D,L-lactic acid) (PLA) and PLA-PEG (polyethyleneglycol)] followed by solvent evaporation. The size distribution and zeta potential of the NCs preparations were determined in a Zetasizer by photon correlation spectroscopy and laser Doppler anemometry, respectively. Free and encapsulated 99mTc-fluconazole were administered intravenously in immunosuppressed mice bearing a local infection induced by Candida Albicans inoculation in the right thigh muscle. At pre-established time intervals, tissues and organs of interest were removed and radioactivity was measured in an automatic gamma radiation counter. RESULTS: The NCs diameter was between 200 and 400â¯nm with negative zeta potential values. Free 99mTc-fluconazole was more rapidly eliminated by the renal system compared to the encapsulated drug in NCs, which remained longer in blood circulation. The uptake of conventional NCs by mononuclear phagocyte system organs was higher than the one demonstrated by the surface-modified NCs. Both NCs remained longer in the infectious focus when compared to free 99mTc-fluconazole, but the results did not show a significant difference between NC formulations. CONCLUSION: These data indicate that these NCs might represent a therapeutic alternative for the treatment of candidiasis, once they remain more time in the infectious focus, allowing high retention of 99mTc-fluconazole at this site.
Asunto(s)
Candida albicans/fisiología , Candidiasis/metabolismo , Fluconazol/farmacocinética , Tecnecio/farmacocinética , Administración Intravenosa , Animales , Candida albicans/efectos de los fármacos , Candidiasis/sangre , Candidiasis/patología , Modelos Animales de Enfermedad , Fluconazol/administración & dosificación , Fluconazol/sangre , Fluconazol/farmacología , Masculino , Ratones , Músculos/patología , Nanocápsulas/química , Radiofármacos/administración & dosificación , Radiofármacos/sangre , Radiofármacos/farmacocinética , Radiofármacos/farmacología , Tecnecio/administración & dosificación , Tecnecio/sangre , Tecnecio/farmacología , Distribución Tisular/efectos de los fármacosRESUMEN
ABSTRACT Fluconazole is extensively used for the treatment of candidiasis and cryptococcosis. Among other factors, successful treatment is related to appropriate fluconazole levels in blood and cerebrospinal fluid. In the present study, fluconazole levels were determined in 15 patients, 14 of whom had AIDS and 13 had neurocryptococcosis. The only selection criterion was treatment with fluconazole, which was performed with a generic or similar form of the drug. Fluconazole level was determined by high performance liquid chromatography and the susceptibility profile of Cryptococcus spp. isolated from the patients was assessed by broth microdilution. Blood and cerebrospinal fluid fluconazole levels were found to be related to the fluconazole daily dose, and exceeded the minimum inhibitory concentration of this antifungal for the Cryptococcus spp. isolates. A good correlation was observed between serum and cerebrospinal fluid drug concentration. In conclusion, treatment with non-original fluconazole under usual medical practice conditions results in appropriate blood and cerebrospinal fluid levels of the drug for inhibiting Cryptococcus spp. susceptible to this antifungal drug. The relatively common failures of neurocryptococcosis treatment appear not to be due to insufficient fluconazole levels in the cerebrospinal fluid, especially with the use of daily doses of 400-800 mg.
Asunto(s)
Humanos , Adulto , Persona de Mediana Edad , Fluconazol/líquido cefalorraquídeo , Fluconazol/sangre , Criptococosis/tratamiento farmacológico , Antifúngicos/líquido cefalorraquídeo , Antifúngicos/sangre , Valores de Referencia , Candidiasis/líquido cefalorraquídeo , Candidiasis/tratamiento farmacológico , Candidiasis/sangre , Pruebas de Sensibilidad Microbiana , Fluconazol/administración & dosificación , Cromatografía Líquida de Alta Presión , Resultado del Tratamiento , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Estadísticas no Paramétricas , Criptococosis/líquido cefalorraquídeo , Criptococosis/sangre , Cryptococcus/aislamiento & purificación , Cryptococcus/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Histoplasmosis/líquido cefalorraquídeo , Histoplasmosis/tratamiento farmacológico , Histoplasmosis/sangre , Antifúngicos/administración & dosificaciónRESUMEN
Sirolimus, an immunosuppressant, is indicated post-allogeneic stem cell transplant to reduce the risk of graft-versus-host-disease. Sirolimus is metabolized by cytochrome P450 3A4 and is a substrate of the P-glycoprotein (P-gp) drug efflux pump. Interactions with known inhibitors of the CYP3A4 enzyme and P-glycoprotein, such as fluconazole, are anticipated. Co-administration of fluconazole leads to an increase in sirolimus blood concentrations due to an inhibition of metabolism. The discontinuation of fluconazole will likely result in a decline in sirolimus blood concentrations, leaving patients at risk of graft-versus-host-disease. We report on three patients managed by the Hematology, Oncology Blood and Marrow Transplant Program at the Alberta Children's Hospital. The discontinuation of fluconazole showed a marked reduction in sirolimus trough levels, requiring >200% increase in sirolimus dose to achieve therapeutic levels.
Asunto(s)
Trasplante de Médula Ósea/tendencias , Manejo de la Enfermedad , Fluconazol/sangre , Enfermedad Injerto contra Huésped/sangre , Inmunosupresores/sangre , Sirolimus/sangre , Adolescente , Alberta , Trasplante de Médula Ósea/efectos adversos , Niño , Interacciones Farmacológicas/fisiología , Femenino , Fluconazol/uso terapéutico , Enfermedad Injerto contra Huésped/tratamiento farmacológico , Humanos , Inmunosupresores/uso terapéutico , Masculino , Sirolimus/uso terapéuticoRESUMEN
Fluconazole is extensively used for the treatment of candidiasis and cryptococcosis. Among other factors, successful treatment is related to appropriate fluconazole levels in blood and cerebrospinal fluid. In the present study, fluconazole levels were determined in 15 patients, 14 of whom had AIDS and 13 had neurocryptococcosis. The only selection criterion was treatment with fluconazole, which was performed with a generic or similar form of the drug. Fluconazole level was determined by high performance liquid chromatography and the susceptibility profile of Cryptococcus spp. isolated from the patients was assessed by broth microdilution. Blood and cerebrospinal fluid fluconazole levels were found to be related to the fluconazole daily dose, and exceeded the minimum inhibitory concentration of this antifungal for the Cryptococcus spp. isolates. A good correlation was observed between serum and cerebrospinal fluid drug concentration. In conclusion, treatment with non-original fluconazole under usual medical practice conditions results in appropriate blood and cerebrospinal fluid levels of the drug for inhibiting Cryptococcus spp. susceptible to this antifungal drug. The relatively common failures of neurocryptococcosis treatment appear not to be due to insufficient fluconazole levels in the cerebrospinal fluid, especially with the use of daily doses of 400-800mg.
Asunto(s)
Antifúngicos/sangre , Antifúngicos/líquido cefalorraquídeo , Criptococosis/tratamiento farmacológico , Fluconazol/sangre , Fluconazol/líquido cefalorraquídeo , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Adulto , Antifúngicos/administración & dosificación , Candidiasis/sangre , Candidiasis/líquido cefalorraquídeo , Candidiasis/tratamiento farmacológico , Cromatografía Líquida de Alta Presión , Criptococosis/sangre , Criptococosis/líquido cefalorraquídeo , Cryptococcus/efectos de los fármacos , Cryptococcus/aislamiento & purificación , Relación Dosis-Respuesta a Droga , Fluconazol/administración & dosificación , Histoplasmosis/sangre , Histoplasmosis/líquido cefalorraquídeo , Histoplasmosis/tratamiento farmacológico , Humanos , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Valores de Referencia , Estadísticas no Paramétricas , Resultado del TratamientoRESUMEN
Fluconazole is an antifungal agent used for the treatment of invasive candidiasis, a leading cause of morbidity and mortality in premature infants. Population pharmacokinetic (PK) models of fluconazole in infants have been previously published by Wade et al. (Antimicrob Agents Chemother 52:4043-4049, 2008, https://doi.org/10.1128/AAC.00569-08) and Momper et al. (Antimicrob Agents Chemother 60:5539-5545, 2016, https://doi.org/10.1128/AAC.00963-16). Here we report the results of the first external evaluation of the predictive performance of both models. We used patient-level data from both studies to externally evaluate both PK models. The predictive performance of each model was evaluated using the model prediction error (PE), mean prediction error (MPE), mean absolute prediction error (MAPE), prediction-corrected visual predictive check (pcVPC), and normalized prediction distribution errors (NPDE). The values of the parameters of each model were reestimated using both the external and merged data sets. When evaluated with the external data set, the model proposed by Wade et al. showed lower median PE, MPE, and MAPE (0.429 µg/ml, 41.9%, and 57.6%, respectively) than the model proposed by Momper et al. (2.45 µg/ml, 188%, and 195%, respectively). The values of the majority of reestimated parameters were within 20% of their respective original parameter values for all model evaluations. Our analysis determined that though both models are robust, the model proposed by Wade et al. had greater accuracy and precision than the model proposed by Momper et al., likely because it was derived from a patient population with a wider age range. This study highlights the importance of the external evaluation of infant population PK models.
Asunto(s)
Antifúngicos/farmacocinética , Candida/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Fluconazol/farmacocinética , Modelos Estadísticos , Antifúngicos/sangre , Disponibilidad Biológica , Candida/crecimiento & desarrollo , Candida/patogenicidad , Candidiasis/microbiología , Candidiasis/patología , Ensayos Clínicos como Asunto , Esquema de Medicación , Femenino , Fluconazol/sangre , Humanos , Lactante , Recién Nacido , Recien Nacido Prematuro , Masculino , Valor Predictivo de las PruebasRESUMEN
BACKGROUND: A fast and easy-to-use liquid chromatography-tandem mass spectrometry method for the determination and quantification of 6 triazoles [fluconazole (FLZ), isavuconazole (ISZ), itraconazole (ITZ), hydroxy-itraconazole (OH-ITZ), posaconazole (PSZ), and voriconazole (VRZ)] in human plasma and serum was developed and validated for therapeutic drug monitoring. METHODS: Sample preparation was based on protein precipitation with acetonitrile and subsequent centrifugation. Isotope-labeled analogues for each analyte were used as internal standards. Chromatographic separation was achieved using a 50 × 2.1 mm, 1.9 µm polar Hypersil Gold C18 column and mobile phase consisting of 0.1% formic acid/acetonitrile (45%/55%, vol/vol) at a flow rate of 340 µL/min. The triazoles were simultaneously detected using a triple-stage quadrupole mass spectrometer operated in selected reaction monitoring mode with positive heated electrospray ionization within a single runtime of t = 3.00 minutes. RESULTS: Linearity of all azole concentration ranges was verified by the Mandel test and demonstrated for all azoles. All calibration curves were linear and fitted using least squares regression with a weighting factor of the reciprocal concentration. Limits of detection (µg/L/L) were FLZ, 9.3; ISZ, 0.3; ITZ, 0.6; OH-ITZ, 8.6; PSZ, 3.4; and VRZ, 2.1. The lower limits of quantitation (µg/L/liter) were FLZ, 28.3; ISZ, 1.0; ITZ, 1.7; OH-ITZ, 26.2; PSZ, 10.3; and VRZ, 6.3. Intraday and interday precisions ranged from 0.6% to 6.6% for all azoles. Intraday and interday accuracies (%bias) of all analytes were within 10.5%. In addition, we report on a 29-year-old white woman (94 kg body weight) with a history of acute myeloid leukemia who underwent stem cell transplantation. Because of diagnosis of aspergillus pneumonia, antifungal pharmacotherapy was initiated with different application modes and dosages of ISZ, and plasma concentrations were monitored over a time period of 6 months. CONCLUSIONS: A precise and highly sensitive liquid chromatography-tandem mass spectrometry method was developed that enables quantification of triazoles in plasma and serum matrix across therapeutically relevant concentration ranges. It was successfully implemented in our therapeutic drug monitoring routine service and is suitable for routine monitoring of antifungal therapy and in severely ill patients.
Asunto(s)
Antifúngicos/sangre , Cromatografía Liquida/métodos , Monitoreo de Drogas/métodos , Plasma/metabolismo , Espectrometría de Masas en Tándem/métodos , Acetonitrilos/sangre , Adulto , Calibración , Femenino , Fluconazol/sangre , Humanos , Indicadores y Reactivos/química , Marcaje Isotópico/métodos , Itraconazol/sangre , Nitrilos/sangre , Piridinas/sangre , Reproducibilidad de los Resultados , Triazoles/sangre , Voriconazol/sangreRESUMEN
Candida auris is an emerging multidrug-resistant threat. The pharmacodynamics of three antifungal classes against nine C. auris strains was explored using a murine invasive candidiasis model. The total drug median pharmacodynamic (PD) target associated with net stasis was a fluconazole AUC/MIC (the area under the concentration-time curve over 24 h in the steady state divided by the MIC) of 26, an amphotericin B Cmax/MIC (maximum concentration of drug in serum divided by the MIC) of 0.9, and a micafungin AUC/MIC of 54. The micafungin PD targets for C. auris were ≥20-fold lower than those of other Candida species in this animal model. Clinically relevant micafungin exposures produced the most killing among the three classes.
Asunto(s)
Anfotericina B/farmacocinética , Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Candida/efectos de los fármacos , Candidiasis Invasiva/tratamiento farmacológico , Candidiasis/tratamiento farmacológico , Equinocandinas/farmacocinética , Equinocandinas/uso terapéutico , Fluconazol/farmacocinética , Fluconazol/uso terapéutico , Lipopéptidos/farmacocinética , Lipopéptidos/uso terapéutico , Anfotericina B/sangre , Animales , Antifúngicos/sangre , Antifúngicos/farmacocinética , Candida/aislamiento & purificación , Candida/patogenicidad , Candidiasis/microbiología , Candidiasis Invasiva/microbiología , Modelos Animales de Enfermedad , Farmacorresistencia Fúngica Múltiple , Equinocandinas/sangre , Fluconazol/sangre , Humanos , Lipopéptidos/sangre , Micafungina , Ratones , Pruebas de Sensibilidad MicrobianaRESUMEN
Amphotericin B (AMB), fluconazole (FZ), and fluorocytosine (FC) are recommended for HIV-associated cryptococcal meningitis (CM) patients as preferred antibiotics. This study presents a fast and automated online-dual-solid phase extraction (SPE)-LC coupled with high resolution mass spectrometer (HRMS) method to simultaneously measure the concentrations of AMB, FZ, and FC in human plasma and cerebrospinal fluid (CSF). Automated sample clean-up was performed on the human plasma and CSF samples with stop-flow heart-cutting two dimensional (2D) separation using a online-dual-SPE system, allowing retention and accumulation of AMB, FZ, and carbamazepine (CBZ, Internal standard (IS)) by the Oasis®HLB cartridge, and retention and accumulation of FC and 5-methylcytosine hydrochloride (MC, IS) by the HyperSep Hypercarb cartridge respectively. Followed by LC elution, quantification by Q-Exactive Hybrid Quadrupole-Orbitrap with targeted-selected ion monitoring (t-SIM) mode was applied to simultaneously determine the concentrations of AMB, FZ and FC. The bioanalysis was achieved in a total running time of 7min. The method was fully validated according to FDA guidelines. The lowest limit of quantification (LLOQ) was 0.04, 0.04, and 0.40µgmL-1 for AMB, FZ, and FC, respectively. AMB, FZ, and FC levels were linear in the ranges of 0.04-2.00µgmL-1, 0.04-2.00µgmL-1 and 0.40-20.00µgmL-1, respectively. The method showed good performance for human plasma and CSF samples with linearity (R2>0.99), intra-day and inter-day precision (relative standard deviation, RSD<4.32% and <4.06%, respectively), recovery (89.93-93.28% and 90.09-93.58%, respectively) and matrix effect (96.35-103.78% and 92.32-101.48%, respectively). The validated method was successfully applied in real samples of Chinese patients. Overall, our results indicate that this fully automated, sensitive, and reliable online-dual-SPE-LC-HRMS method is effective for therapeutic drug monitoring (TDM) of AMB, FZ, and FC levels.
Asunto(s)
Anfotericina B/análisis , Cromatografía Liquida/métodos , Monitoreo de Drogas/métodos , Fluconazol/análisis , Flucitosina/análisis , Extracción en Fase Sólida/métodos , Espectrometría de Masas en Tándem/métodos , Anfotericina B/sangre , Anfotericina B/líquido cefalorraquídeo , Antifúngicos/análisis , Antifúngicos/sangre , Antifúngicos/líquido cefalorraquídeo , Fluconazol/sangre , Fluconazol/líquido cefalorraquídeo , Flucitosina/sangre , Flucitosina/líquido cefalorraquídeo , Humanos , Sistemas en LíneaRESUMEN
BACKGROUND: Triazole antifungals are essential to the treatment and prophylaxis of fungal infections. Significant pharmacokinetic variability combined with a clinical need for faster turnaround times has increased demand for in-house therapeutic drug monitoring of these drugs, which is best performed using mass spectrometry-based platforms. However, technical and logistical obstacles to implementing these platforms in hospital laboratories have limited their widespread utilization. Here, we present the development and validation of a fast and simple ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to measure fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole in human serum suitable for incorporation into a hospital clinical laboratory. METHODS: Serum samples (20 µL) were prepared using protein precipitation in the presence of deuterated internal standards. Chromatographic separation was accomplished using reversed phase UPLC and analysis was performed using positive-mode electrospray ionization and collision-induced dissociation MS. RESULTS: Total analytical run time was 3 min. All analytes demonstrated linearity (r2>0.998) from 0.1 to 10 µg/mL (1-100 µg/mL for fluconazole), acceptable accuracy and precision (%DEV<15% and %CV<15% at all levels tested), suitable stability under relevant storage conditions, and correlated well with reference laboratory results. CONCLUSIONS: A simple and rapid UPLC-MS/MS method for monitoring multiple triazole antifungals was developed with a focus on the needs of hospital laboratories. The assay is suitable for clinical utilization and management of patients on these medications.
Asunto(s)
Antifúngicos/sangre , Análisis Químico de la Sangre/métodos , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Fluconazol/sangre , Humanos , Itraconazol/análogos & derivados , Itraconazol/sangre , Límite de Detección , Reproducibilidad de los Resultados , Factores de Tiempo , Triazoles/sangre , Voriconazol/sangreRESUMEN
Ultrafiltration is a rapid and convenient method to determine the free concentrations of drugs in plasma. Several ultrafiltration devices based on Eppendorf cups are commercially available, but are not validated for such use by the manufacturer. Plasma pH, temperature and relative centrifugal force as well as membrane type can influence the results. In the present work, we developed an ultrafiltration method in order to determine the free concentrations of linezolid or fluconazole, both neutral and moderately lipophilic antiinfective drugs for parenteral as well as oral administration, in plasma of patients. Whereas both substances behaved relatively insensitive in human plasma regarding variations in pH (7.0-8.5), temperature (5-37°C) or relative centrifugal force (1000-10.000xg), losses of linezolid were observed with the Nanosep Omega device due to adsorption onto the polyethersulfone membrane (unbound fraction 75% at 100mg/L and 45% at 0.1mg/L, respectively). No losses were observed with Vivacon which is equipped with a membrane of regenerated cellulose. With fluconazole no differences between Nanosep and Vivacon were observed. Applying standard conditions (pH 7.4/37°C/1000xg/20min), the mean unbound fraction of linezolid in pooled plasma from healthy volunteers was 81.5±2.8% using Vivacon, that of fluconazole was 87.9±3.5% using Nanosep or 89.4±3.3% using Vivacon. The unbound fraction of linezolid was 85.4±3.7% in plasma samples from surgical patients and 92.1±6.2% in ICU patients, respectively. The unbound fraction of fluconazole was 93.9±3.3% in plasma samples from ICU patients.
Asunto(s)
Antiinfecciosos/sangre , Fluconazol/sangre , Linezolid/sangre , Ultrafiltración/métodos , Antiinfecciosos/análisis , Antiinfecciosos/aislamiento & purificación , Celulosa/aislamiento & purificación , Cromatografía Líquida de Alta Presión/métodos , Fluconazol/análisis , Fluconazol/aislamiento & purificación , Humanos , Linezolid/análisis , Linezolid/aislamiento & purificación , Polímeros/aislamiento & purificación , Unión Proteica , Sulfonas/aislamiento & purificaciónRESUMEN
Our objective was to describe the population pharmacokinetics of fluconazole in a cohort of critically ill nonobese, obese, and morbidly obese patients. Critically ill patients prescribed fluconazole were recruited into three body mass index (BMI) cohorts, nonobese (18.5 to 29.9 kg/m2), obese (30.0 to 39.9 kg/m2), and morbidly obese (≥40 kg/m2). Serial fluconazole concentrations were determined using a validated chromatographic method. Population pharmacokinetic analysis and Monte Carlo dosing simulations were undertaken with Pmetrics. Twenty-one critically ill patients (11 male) were enrolled, including obese (n = 6) and morbidly obese (n = 4) patients. The patients mean ± standard deviation (SD) age, weight, and BMI were 54 ± 15 years, 90 ± 24 kg, and 31 ± 9 kg/m2, respectively. A two-compartment linear model described the data adequately. The mean ± SD population pharmacokinetic parameter estimates were clearance (CL) of 0.95 ± 0.48 liter/h, volume of distribution of the central compartment (Vc) of 15.10 ± 11.78 liter, intercompartmental clearance from the central to peripheral compartment of 5.41 ± 2.28 liter/h, and intercompartmental clearance from the peripheral to central compartment of 2.92 ± 4.95 liter/h. A fluconazole dose of 200 mg daily was insufficient to achieve an area under the concentration-time curve for the free, unbound drug fraction/MIC ratio of 100 for pathogens with MICs of ≥2 mg/liter in patients with BMI of >30 kg/m2 A fluconazole loading dose of 12 mg/kg and maintenance dose of 6 mg/kg/day achieved pharmacodynamic targets for higher MICs. A weight-based loading dose of 12 mg/kg followed by a daily maintenance dose of 6 mg/kg, according to renal function, is required in critically ill patients for pathogens with a MIC of 2 mg/liter.
Asunto(s)
Antifúngicos/farmacocinética , Candida/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Fluconazol/farmacocinética , Modelos Estadísticos , Obesidad Mórbida/tratamiento farmacológico , Adulto , Anciano , Antifúngicos/sangre , Área Bajo la Curva , Índice de Masa Corporal , Candida/crecimiento & desarrollo , Candidiasis/complicaciones , Candidiasis/microbiología , Candidiasis/patología , Enfermedad Crítica , Esquema de Medicación , Femenino , Fluconazol/sangre , Humanos , Unidades de Cuidados Intensivos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Método de Montecarlo , Obesidad Mórbida/complicaciones , Obesidad Mórbida/microbiología , Obesidad Mórbida/patología , Estudios ProspectivosRESUMEN
Fluconazole is a renally-eliminated antifungal commonly used to treat Candida species infections. In critically-ill patients receiving prolonged intermittent renal replacement therapy (PIRRT), limited pharmacokinetic (PK) data are available to guide fluconazole dosing. We used previously-published fluconazole clearance data and PK data of critically-ill patients with acute kidney injury to develop a PK model with the goal of determining a therapeutic dosing regimen for critically-ill patients receiving PIRRT. Monte Carlo simulations were performed to create a virtual cohort of patients receiving different fluconazole dosing regimens. Plasma drug concentration-time profiles were evaluated on the probability of attaining a mean 24-hour area under the drug concentration-time curve to minimum inhibitory concentration ratio (AUC24h : MIC) of 100 during the initial 48 hours of antifungal therapy. At the susceptibility breakpoint of Candida albicans (2 mg/L), 93 - 96% of simulated subjects receiving PIRRT attained the pharmacodynamic target with a fluconazole 800-mg loading dose plus 400 mg twice daily (q12h or pre and post PIRRT) regimen. Monte Carlo simulations of a PK model of PIRRT provided a basis for the development of an informed fluconazole dosing recommendation when PK data was limited. This finding should be validated in the clinical setting.